![](/images/graphics-bg.png)
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
Joint Authors
Chuah, Seng-Kee
Hu, Tsung-Hui
Lee, Chen-Hsiang
Lu, Lung-Sheng
Hu, Ming-Luen
Kuo, Yuan-Hung
Yen, Yi-Hao
Chiu, Chien-Hua
Kuo, Chung-Huang
Chiu, Yi-Chun
Wu, Keng-Liang
Kuo, Chung-Mou
Chiou, Shue-Shian
Liang, Chih-Ming
Tai, Wei-Chen
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-19
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
This prospective study was to assess the efficacy of nonbismuth containing quadruple therapy as first-line H.
pylori treatment and to determine the clinical factors influencing patient outcome.
We enrolled 200 H.
pylori-infected naïve patients.
They were prescribed either a 7-day nonbismuth containing quadruple therapy group (EACM, esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, metronidazole 500 mg twice daily, and clarithromycin 500 mg twice daily) or a 7-day standard triple therapy group (EAC, esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily).
Follow-up studies to assess treatment responses were carried out 8 weeks later.
The eradication rates attained by EACM and EAC groups were 95.6% (95% confidence interval [CI] = 89.4%–98.3%) and 79.3% (95% CI = 70%–86.4%) in the per-protocol analysis (P < 0.001) and 88% (95% CI = 80.2%–93.0%) and 73% (95% I = 63.6%–80.3%) in the intention-to-treat analysis (P = 0.007).
Clarithromycin resistance, metronidazole resistance, and dual clarithromycin and metronidazole resistances were the clinical factors influencing H.
pylori eradication in EACM group.
Clarithromycin resistance and dual clarithromycin and metronidazole resistances were the influential factor for EAC treatment.
In conclusion, the results suggest that 7-day nonbismuth containing quadruple therapy could achieve a grade “A” report card for first-line H.
pylori treatment.
American Psychological Association (APA)
Tai, Wei-Chen& Liang, Chih-Ming& Lee, Chen-Hsiang& Chiu, Chien-Hua& Hu, Ming-Luen& Lu, Lung-Sheng…[et al.]. 2015. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. BioMed Research International،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1056169
Modern Language Association (MLA)
Tai, Wei-Chen…[et al.]. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. BioMed Research International No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1056169
American Medical Association (AMA)
Tai, Wei-Chen& Liang, Chih-Ming& Lee, Chen-Hsiang& Chiu, Chien-Hua& Hu, Ming-Luen& Lu, Lung-Sheng…[et al.]. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1056169
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1056169